Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | RBP4 | P02753 | 1/20 | 0.37 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | SCD | O00767 | 5/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.33 |
| ▸ | IKBKB | O14920 | 2/20 | 0.33 |
| ▸ | CHUK | O15111 | 2/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17455968 | 0.77 | SMN1; SMN2 (0.53) | CYP11B1CYP11B2CYP3A4 | |
| SCHEMBL17455927 | 0.76 | RBP4 (0.53) | RBP4CYP46A1CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL17456007 | 0.76 | TDP1 (0.47) | CYP11B1CYP11B2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL21238938 | 0.75 | CYP11B1 (0.42) | CYP11B1CYP11B2RBP4 | |
| SCHEMBL17455921 | 0.74 | CYP11B1 (0.42) | CYP11B1CYP11B2RBP4PDE10AMAPK14 | |
| SCHEMBL17456018 | 0.74 | CYP11B1 (0.42) | CYP11B1CYP11B2RBP4MAPK14 | |
| SCHEMBL17455954 | 0.74 | ALDH1A1 (0.48) | CYP11B1CYP11B2CYP2C19 | |
| SCHEMBL17456046 | 0.73 | MCHR1 (0.53) | CYP11B1CYP11B2CYP3A4CYP2C9 | |
| SCHEMBL17455925 | 0.73 | HRH1 (0.50) | CYP11B1CYP11B2IKBKBCHUKMAPK14 | |
| SCHEMBL17456064 | 0.73 | RBP4 (0.47) | RBP4SCDIKBKBCHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598398-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-21 | — | — | US | disclosed |
| US-9598398-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-21 | — | — | US | disclosed |
| US-20160024049-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-28 | — | — | US | disclosed |
| US-20160024049-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024049-A1 | HETEROCYCLIC COMPOUND | PSEN1, PSEN2, BACE1 | CYP11B1 88/4885CYP11B2 82/4885RBP4 4341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.